



FIG. 1A




FIG. 1B



FIG. 2A




FIG. 2B



FIG. 3A




FIG. 3B



FIG. 3C




FIG. 3D



FIG. 4A




FIG. 4B



FIG. 5A




FIG. 5B



FIG. 6A




FIG. 6B



FIG. 6C




FIG. 6D

FSHβ 33-53 peptide	Anti-MSLN scFv or sGAD	Linker	Anti-MSLN scFv or sGAD	CD8α-3tag	CD8α-TM	4-1BB-ICD	CD28-ICD	P2A	dnTGFβRII
--------------------	------------------------	--------	------------------------	-----------	---------	-----------	----------	-----	-----------

FIG. 6E




FIG. 6F

FSHβ 33-53 peptide	Anti-MSLN scFv or sGAD	Linker	FSHβ 33-53 peptide	CD8α-3tag	CD8α-TM	4-1BB-ICD	CD28-ICD	P2A	dnTGFβRII
--------------------	------------------------	--------	--------------------	-----------	---------	-----------	----------	-----	-----------

FIG. 6G




FIG. 6H

FIG. 6I




FIG. 6J




FIG. 6L




FIG. 7




FIG. 8




FIG. 9




FIG. 10

Long-term expansion by repetitive stimulation




FIG. 11




FIG. 12




FIG. 13

MSLN/FSHR CAR redirected T cell killing against OVCAR-8 Cells




FIG. 14

MSLN/FSHR CAR redirected T cell killing against OVCAR-8 Cells




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22